Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 159 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dementia Alzheimer Type Clear all
Completed Phase 2 Interventional

Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill

NCT06597058
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MAR
Drug
Lead sponsor
Noah Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Scottsdale, Arizona • Huntington Beach, California • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 18, 2026, 8:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Couples Lived Experience

NCT04863495
View directory record Official record
Conditions
Alzheimer Disease, Dementia of Alzheimer Type
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years and older
Enrollment
544 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Bedford, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease

NCT01928420
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Drug: NIC5-15, Placebo
Drug
Lead sponsor
Humanetics Corporation
Industry
Eligibility
40 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Not applicable Interventional Results available

Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)

NCT03160027
View directory record Official record
Conditions
Dementia, Alzheimer Type
Interventions
Vielight Neuro Gamma
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 18, 2026, 8:16 AM EDT
Terminated No phase listed Observational

Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects

NCT01018927
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Administering three additional MRI images
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 18, 2026, 8:16 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Physical Activity and Community EmPOWERment Project

NCT06740162
View directory record Official record
Conditions
Intellectual Disability, Neurodevelopmental Disorders, Autism Spectrum Disorder, Down Syndrome, Fragile X Syndrome, Cri-du-Chat Syndrome, De Lange Syndrome, Mental Retardation, X-Linked, Prader-Willi Syndrome, Rubinstein-Taybi Syndrome, Trisomy 13 Syndrome, WAGR Syndrome, Williams Syndrome
Interventions
PACE Program
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Fayetteville, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation

NCT04947553
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
Interventions
AXS-05 (dextromethorphan-bupropion), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
45
States / cities
Peoria, Arizona • Tempe, Arizona • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease

NCT00322153
View directory record Official record
Conditions
Dementia of the Alzheimer's Type
Interventions
memantine ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
38
States / cities
Phoenix, Arizona • Costa Mesa, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

NCT00153010
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NS 2330 (Tesofensine)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 85 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
80
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT01266525
View directory record Official record
Conditions
Dementia Alzheimer's Type
Interventions
SAR110894, placebo (for SAR110894), Donepezil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 18, 2026, 8:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Dominantly Inherited Alzheimer Network (DIAN)

NCT00869817
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2031
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Not applicable Interventional Results available

An Electronic Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions

NCT04851691
View directory record Official record
Conditions
Alzheimer Disease, Dementia Alzheimers, Dementia of Alzheimer Type
Interventions
EHR CDS, Usual Care
Behavioral · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 18, 2026, 8:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Health & the Microbiome

NCT06039267
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Dementia, Alzheimer Disease 1
Interventions
Gut Microbiome Testing
Other
Lead sponsor
George Washington University
Other
Eligibility
50 Years to 90 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 18, 2026, 8:16 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT06647498
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Remternetug, Matching Placebo (Remternetug)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
13
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 18, 2026, 8:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Preclinical Imaging Biomarkers of Alzheimer's Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study

NCT05350514
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes, Youth Onset
Interventions
PI-2620 tracer
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Not applicable Interventional Results available

Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial

NCT05860127
View directory record Official record
Conditions
Dementia, Cognitive Impairment, Mild, Dementia, Vascular, Dementia, Mixed, Dementia With Lewy Bodies, Dementia Frontal, Dementia Moderate, Dementia of Alzheimer Type, Dementia, Mild
Interventions
Referral for Cognitive Stimulation Therapy, No change to Standard of Care
Behavioral · Other
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Farmington, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 3 Interventional

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

NCT05894954
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Mild
Interventions
Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care, Lifestyle including diet, exercise, stress management
Dietary Supplement · Combination Product · Behavioral
Lead sponsor
Alzheimer's Prevention and Reversal Project, Inc.
Other
Eligibility
45 Years to 76 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Folsom, California • San Rafael, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

NCT01083316
View directory record Official record
Conditions
Amyloidosis
Interventions
Bortezomib, Dexamethasone, Melphalan
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

Nefiracetam in the Treatment of Alzheimer's Disease

NCT00001933
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Nefiracetam
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

NCT01922258
View directory record Official record
Conditions
Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions
Brexpiprazole, OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
28
States / cities
Imperial, California • Lakewood, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 3 Interventional Results available

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

NCT00428090
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 18, 2026, 8:16 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Care Planning for a Loved One With Dementia: Knowledge, Preparing for Decisions, and Emotions

NCT05165186
View directory record Official record
Conditions
Dementia, Dementia Frontotemporal, Dementia Alzheimers, Dementia, Mild, Dementia Moderate, Dementia Severe, Caregiver Burnout, Caregiver Stress Syndrome
Interventions
Video Intervention Arm
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease

NCT04491006
View directory record Official record
Conditions
Alzheimer Disease, Dementia of Alzheimer Type
Interventions
ATH-1017, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
55 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Santa Ana, California • West Palm Beach, Florida • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 1 Interventional

BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)

NCT02502253
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
grape seed polyphenolic extract, resveratrol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 18, 2026, 8:16 AM EDT